Does smoking impact dopamine neuronal loss in de novo Parkinson disease?

Yoonju Lee, Jungsu S. Oh, Seok Jong Chung, Su Jin Chung, Soo Jong Kim, Chung Mo Nam, Phil Hyu Lee, Jae Seung Kim, Young H. Sohn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study analyzed data from dopamine transporter (DAT) positron emission tomographic scans of 282 male patients with de novo Parkinson disease to investigate whether smoking impacts striatal dopamine neuronal degeneration. Mean DAT activity in the posterior (p = 0.016) and ventral putamen (p = 0.028) was higher in 44 current smokers in comparison to 105 ex-smokers and 133 never-smokers. The severity of baseline motor deficits and the longitudinal increases in levodopa-equivalent doses during follow-up were similar among the 3 groups. These results suggest that current smoking, but not past smoking, protects dopamine neuronal degeneration in the sensorimotor striatum with no additional clinical benefits. Ann Neurol 2017;82:850–854.

Original languageEnglish
Pages (from-to)850-854
Number of pages5
JournalAnnals of Neurology
Volume82
Issue number5
DOIs
Publication statusPublished - 2017 Nov

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Does smoking impact dopamine neuronal loss in de novo Parkinson disease?'. Together they form a unique fingerprint.

  • Cite this

    Lee, Y., Oh, J. S., Chung, S. J., Chung, S. J., Kim, S. J., Nam, C. M., Lee, P. H., Kim, J. S., & Sohn, Y. H. (2017). Does smoking impact dopamine neuronal loss in de novo Parkinson disease? Annals of Neurology, 82(5), 850-854. https://doi.org/10.1002/ana.25082